A Phase 2 Study of the MEK Inhibitor Trametinib in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Overview

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment.

Description

The purpose of this study is to determine the objective response rate to trametinib in children with recurrent or refractory juvenile myelomonocytic leukemia (JMML).

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: juvenile myelomonocytic leukemia
  • Age: - 21 Years
  • Gender: Male or Female

Inclusion Criteria
Patients must have had histologic verification of juvenile myelomonocytic leukemia (JMML) at original diagnosis and currently have relapsed or refractory disease
Patients with refractory or relapsed JMML must have had at least one cycle of intensive frontline therapy or a deoxyribonucleic acid (DNA) demethylating agent with persistence of disease, defined by clinical symptoms or the presence of a clonal abnormality
Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment
Patients must not be known to be refractory to red blood cell or platelet transfusions
Exclusion Criteria
Patients who are pregnant or breast-feeding
Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment
Patients who are currently receiving another investigational drug
Patients who are currently receiving other anti-cancer agents
Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant
Any medications for treatment of left ventricular systolic dysfunction
Patients who are unable to swallow capsules or liquid
Patients who have an uncontrolled infection
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive disease) within the prior 3 months
Patients with a history of current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
Patients with a history of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease(s) such as hypertension, diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes)


Additional Information:
Participants will not be paid for their participation.

Updated on 30 Nov 2022 . Study ID: TX8418

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center